Breast Cancer Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Mridula George, MD, Rutgers Cancer institute of New Jersey, discusses the addition of HER2 targeted agents within the last two decades that have been studied in the metastatic, adjuvant, and the…
View More
Olufunmilayo Olopade, MD, FACP, discusses the overhaul of precision oncology for true equity in cancer care, and brings focus to patient populations who have been understudied.
View More
Anthony Lucci, MD, highlights the significant results of a study on the role of MRM in patients with de novo stage IV inflammatory breast cancer.
View More
Adam Brufsky, MD, PhD, discusses evolving strategies in neoadjuvant/adjuvant treatment of early-stage TNBC.
View More
At the annual Miami Breast Cancer Conference, Kelly Hunt, MD, discussed the use of neoadjuvant endocrine therapy for patients with breast cancer.
View More
Anees Chagpar, MD, discusses her presentation on neoadjuvant chemo for cN0 breast cancer from the Miami Breast Cancer Conference.
View More
Dr Hurvitz discusses the HER2CLIMB and HER2CLIMB-02 trials examining tucatinib's activity and safety in patients with HER2-positive metastatic breast cancer.
View More
Mattea Reinisch, MD, highlights the final efficacy and safety results of the phase 3b, multi-center, open-label Ribecca trial for women with ER+, HER2- locally advanced or metastatic breast cancer,…
View More
Dr Linden shares encouraging results from the AMEERA-1 trial of SAR439859 for ER+/HER2- metastatic breast cancer, presented at the virtual 2020 SABCS Annual Meeting.
View More
Stay in the know.
OncNet Newsletter